Library

Respiratory and antinociceptive effects of NOP-MOP agonist cebranopadol versus full opioid receptor agonist oxycodone: a comparison in healthy volunteers.

11 December 2025. doid: 10.1097/ALN.0000000000005894

Jansen S, Olofsen E, Moss L, Grieco JC, Lesnick ML, Hackworth JC, van Velzen M, Dahan A, Sarton E, Groeneveld GJ, Niesters M, van der Schrier R

View publication

The novel analgesic cebranopadol targets the nociceptin (NOP) and mu-opioid (MOP) receptor, acting as a novel full dual NOP-MOP-receptor agonist, with possible differences in respiratory effects compared to selective MOP-opioids like oxycodone.

Advancing the boundaries of clinical drug development

Wondering how we can help you? Reach out to us.

Get in contact
contact